title: Development and validation of an ELISA for quantification of soluble IFN-β receptor: assessment in multiple sclerosis.
abstract: OBJECTIVE
  The soluble isoform of the IFN-β receptor (sIFNAR2) can bind IFN-β and modulate its activity, although its role in autoimmune diseases remains unknown.
  
  
  METHODS
  A recombinant human sIFNAR2 protein was cloned, expressed and purified after which we developed and validated an ELISA for its quantification in human serum. Serum sIFNAR2 were assessed in multiple sclerosis (MS) patients and healthy controls.
  
  
  RESULTS
  The ELISA has a dynamic range of 3.9-250 ng/ml and a detection limit of 2.44 ng/ml. Serum sIFNAR2 were significantly lower in untreated-MS patients than in healthy controls.
  
  
  CONCLUSIONS
  The ELISA is suitable for quantification of sIFNAR2 in serum and should facilitate the study of sIFNAR2 in neuroimmunological diseases such as MS.
authors.affiliation: Unidad de Gestión Clínica de Neurociencias. Instituto de Biomedicina de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain.
authors.forename: Teresa
authors.initials: T
authors.lastname: Órpez-Zafra
authors.affiliation: Departamento de Farmacología y Pediatría, Facultad de Medicina, Instituto de Biomedicina de Málaga (IBIMA). Universidad de Málaga, Spain.
authors.forename: Jose
authors.initials: J
authors.lastname: Pavía
authors.affiliation: Unidad de Gestión Clínica de Neurociencias. Instituto de Biomedicina de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain.
authors.forename: Maria J
authors.initials: MJ
authors.lastname: Pinto-Medel
authors.affiliation: Unidad de Gestión Clínica de Neurociencias. Instituto de Biomedicina de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain.
authors.forename: Isaac
authors.initials: I
authors.lastname: Hurtado-Guerrero
authors.affiliation: Unidad de Gestión Clínica de Neurociencias. Instituto de Biomedicina de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain.
authors.forename: Jose L
authors.initials: JL
authors.lastname: Rodriguez-Bada
authors.affiliation: Departamento de Farmacología y Pediatría, Facultad de Medicina, Instituto de Biomedicina de Málaga (IBIMA). Universidad de Málaga, Spain.
authors.forename: Elisa
authors.initials: E
authors.lastname: Martín Montañez
authors.affiliation: Unidad de Gestión Clínica de Neurociencias. Instituto de Biomedicina de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain.
authors.forename: Óscar
authors.initials: Ó
authors.lastname: Fernández
authors.affiliation: Unidad de Gestión Clínica de Neurociencias. Instituto de Biomedicina de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Leyva
authors.affiliation: Unidad de Gestión Clínica de Neurociencias. Instituto de Biomedicina de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain.
authors.forename: Begoña
authors.initials: B
authors.lastname: Oliver-Martos
mesh_terms: D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D006801:Humans; D009103:Multiple Sclerosis / Q000097:blood / Q000175:diagnosis*; D053633:Receptor, Interferon alpha-beta / Q000097:blood*; D011994:Recombinant Proteins / Q000378:metabolism*; D015203:Reproducibility of Results
chemical_list: C508033:IFNAR2 protein, human; D011994:Recombinant Proteins; D053633:Receptor, Interferon alpha-beta